ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00823745
Recruitment Status : Completed
First Posted : January 16, 2009
Last Update Posted : March 9, 2009
Sponsor:
Information provided by:
Pfizer

Brief Summary:
This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.

Condition or disease Intervention/treatment Phase
HCV Drug: [14C]-PF-00868554 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study To Evaluate The Metabolism And Excretion Of [14C] PF-00868554 In Healthy Adult Male Subjects
Study Start Date : January 2009
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Arm Intervention/treatment
Experimental: 1
[14C]-PF-00868554
Drug: [14C]-PF-00868554
solution, single dose




Primary Outcome Measures :
  1. The amount of radioactivity recovered in urine and feces, as a percent of the dose. [ Time Frame: 7 weeks ]
  2. The amount of PF-00868554, expressed as a percent of total radioactivity, in plasma, urine, and feces. [ Time Frame: 7 weeks ]
  3. Identification and determination of relative abundance of the metabolites of PF-00868554 in plasma, urine, and feces. [ Time Frame: 7 weeks ]
  4. PK parameters: AUClast, AUCinf, maximum concentration (Cmax), time of maximum concentration (Tmax), and half-life (t1/2) to describe the single dose PK of a) total radioactivity in blood; b) total radioactivity in plasma; c) PF-00868554 in plasma. [ Time Frame: 7 weeks ]

Secondary Outcome Measures :
  1. Safety endpoints including adverse events, clinical laboratory tests, vital signs and ECGs. [ Time Frame: 7 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male, healthy volunteers.

Exclusion Criteria:

  • Females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00823745


Locations
United States, Washington
Pfizer Investigational Site
Tacoma, Washington, United States, 98415
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00823745     History of Changes
Other Study ID Numbers: A8121013
First Posted: January 16, 2009    Key Record Dates
Last Update Posted: March 9, 2009
Last Verified: March 2009